Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI104668

THANK YOU

FOR YOUR INTEREST IN OUR REPORT

Are you interested in exploring our consulting services?

I want to learn more about:

Competitive Intelligence Opportunity Assessment Distribution & Supply Chain Analysis Book a consultation to discuss your needs

Market Entry Strategy Go-to-market Strategy Others (Please specify)

Table of Content

. Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
2. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
3. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
4. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
5. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
6. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
7. Impact of Covid-19 on the Market
Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis, Insights and Forecast – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis, Insights and Forecast – By Country
  1. North America
  2. Europe
  3. Asia pacific
  4. Latin America
  5. Middle East & Africa
North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis – By Country
  1. U.S.
  2. Canada
Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis – By Country
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis – By Country
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis – By Country
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Prophylaxis
    1. Palivizumab
    2. Nirsevimab
    3. MK-1654
    4. Other Prophylaxis (Vaccines)
  2. Treatment
    1. Ribavirin
    2. All New Treatment
      1. JNJ 53718678
      2. Enanta EDP-938
      3. ASCENIV
3. Market Analysis – By End User
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
4. Market Analysis – By Country
  1. GCC Countries
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Key Industry Developments
2. Global Market Share Analysis (2019)
3. Competition Dashboard
4. Comparative Analysis – Major Players
5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  1. AstraZeneca
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  2. Bausch Health Companies Inc
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  3. AbbVie
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  4. Johnson & Johnson Services, Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  5. Sanofi
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  6. Merck & Co., Inc
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  7. Celltrion Inc.
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  8. mAbxience
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
  9. Enanta Pharmaceuticals, Inc
    1. Overview,
    2. Products & services,
    3. SWOT analysis,
    4. Recent developments,
    5. strategies,
    6. financials (based on availability)
Strategic Recommendations

Read Less

List of Figures

Figure 1: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue Breakdown (USD Million, %) by Region, 2019 & 2027

Figure 2: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019 & 2027

Figure 3: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Prophylaxis, 2016-2027

Figure 4: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Treatment, 2016-2027

Figure 5: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Palivizumab, 2016-2027

Figure 6: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Nirsevimab, 2016-2027

Figure 7: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by MK-1654, 2016-2027

Figure 8: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Other Prophylaxis, 2016-2027

Figure 9: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Ribavirin, 2016-2027

Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by JNJ 53718678, 2016-2027

Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Enanta EDP-938, 2016-2027

Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by ASCENIV4, 2016-2027

Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019 & 2027

Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Hospital Pharmacies, 2016-2027

Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Retail Pharmacies, 2016-2027

Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Forecast (USD Million), by Online Pharmacies, 2016-2027

Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Region, 2019 & 2027

Figure 18: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 19: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 20: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 21: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country, 2019 & 2027

Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country, 2019

Figure 24: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 25: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 26: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 27: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 28: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 29: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 30: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 31: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 32: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 33: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 34: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 35: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 36: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 37: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 38: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 39: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 40: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 41: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 42: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by Drug Class, 2019 & 2027

Figure 43: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by Drug Class, 2019

Figure 44: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), by End-user, 2019 & 2027

Figure 45: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), by End-user, 2019

Figure 46: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value (USD Million), By Country/ Sub-region, 2019 & 2027

Figure 47: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share (%), By Country/ Sub-region, 2019

Figure 48: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share (%), By Company, 2019

List of Tables

Table 1: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016–2027

Table 2: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 3: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 4: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016–2027

Table 5: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Region, 2016-2027

Table 6: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 7: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 8: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 9: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 10: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country, 2016-2027

Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 13: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 14: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 15: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 17: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 18: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 19: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 20: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 21: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 22: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 23: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 24: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 25: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027

Table 26: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Drug Class, 2016-2027

Table 27: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Prophylaxis, 2016–2027

Table 28: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by Treatment, 2016–2027

Table 29: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, by End-user, 2016-2027

Table 30: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2016-2027